[Prospects of respiratory syncytial virus vaccines].
The latest vaccines for Respiratory Syncytial Virus (RSV) are reviewed. A ts-1 variant is being studied in the attempt to complete the attenuation of the vaccine strain. Further investigations of live RSV vaccine administered parenterally indicate that a target population over 6 months of age could benefit soon of this preparation.
D000367:Age Factors; D006801:Humans; D007223:Infant; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D010253:Respirovirus Infections / Q000517:prevention & control; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D014765:Viral Vaccines
D014613:Vaccines, Attenuated; D014765:Viral Vaccines
Prospettive di vaccini per il virus respiratorio sinciziale (VRS).